CollPlant Earns $2M AbbVie Milestone, Launches BioFlex and Reports Full Implant Vascularization
CollPlant earned a $2 million AbbVie milestone payment and set up U.S. cGMP logistics for North American distribution of its rhCollagen products. It launched BioFlex DLP 3D bioprinting kits, won U.S. and South Korean patents for its photocurable dermal filler, and achieved full vascularization in preclinical regenerative breast implant studies.
1. Financial Results and AbbVie Milestone
CollPlant reported a $2 million milestone payment from AbbVie in February 2025 after achieving a development trigger in their rhCollagen-based soft tissue filler program. This underscores progress in its collaboration model and could enhance future royalty and commercialization revenues.
2. Distribution Expansion
In October 2025, CollPlant partnered with a U.S.-based logistics center to establish a cGMP-compliant storage and distribution hub for its rhCollagen and BioInk lines across the United States and Canada. The company also strengthened its European network for Vergenix STR to support growing demand in medical aesthetics.
3. Product Launches and Intellectual Property
In February 2026, CollPlant introduced BioFlex, a ready-to-print rhCollagen kit designed for high-resolution DLP 3D bioprinting in academic and industrial R&D. The company also secured U.S. Patent No. 12,186,449 and corresponding South Korean patents covering its photocurable dermal filler technology.
4. Regenerative Breast Implant Progress
Preclinical studies of CollPlant’s 200 cc regenerative breast implants demonstrated full vascularization and rapid tissue ingrowth at six months post-implantation, with no capsule formation or calcifications. These findings support further optimization toward clinical evaluation of durable, immune-compatible breast implants.